Procept Biorobotics Inc. shares slid 6.7% in morning trading to $23.98, extending a multi-session decline that accelerated after Leerink Partners lowered its rating on the stock. On June 11 the firm cut its view to Market Perform from Outperform and trimmed its price target to $29 from $31, citing increasing competitive pressure in the BPH robotic surgery market and reduced conviction in Procept’s near-term commercial trajectory.
Leerink said the decision followed a MEDACorp KOL Pulse Call that centered on commercial trends and competitive dynamics within the BPH space. Feedback from key opinion leaders, including input from a urologist at a multi-specialty practice, prompted the firm to revise its outlook. That downgrade added to earlier signs of analyst caution; other Wall Street firms had already pushed down their targets in recent months, leaving the stock trading well below the consensus price target among the broader analyst community.
The timing of the drop stands out relative to the market backdrop. While the S&P 500 was up 1.5% and the NASDAQ advanced 2.3%, Procept moved against the general risk-on rotation, underperforming major indexes. The stock’s 52-week range - $19.35 to $62.17 - reflects a marked deterioration in sentiment from its highs.
Investors remain focused on several unresolved operational and reimbursement questions that the downgrade highlighted. Concerns persist around capital equipment demand and handpiece utilization, and market participants are also watching for potential reimbursement headwinds tied to Aquablation therapy. Those issues, combined with intensifying competition, have kept pressure on the shares.
In the near term, the Leerink downgrade appears to have been the primary catalyst for the latest leg lower. That action - layered on top of an already prolonged downtrend and continuing competitive anxieties - has amplified selling pressure. Without clear, tangible evidence of procedure volume reacceleration or signs that the competitive landscape is stabilizing, the path of least resistance for the stock appears to remain downward.
What would change the outlook
- Demonstrable reacceleration in procedure volumes tied to Aquablation therapy.
- Signs of stabilization in the competitive landscape for BPH robotic surgery.
Market context
- Procept’s decline occurred amid broad U.S. equity strength, highlighting company-specific pressures.